BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 33259596)

  • 1. Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines.
    Pleyer C; Ali MA; Cohen JI; Tian X; Soto S; Ahn IE; Gaglione EM; Nierman P; Marti GE; Hesdorffer C; Lotter J; Superata J; Wiestner A; Sun C
    Blood; 2021 Jan; 137(2):185-189. PubMed ID: 33259596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL.
    Pleyer C; Laing KJ; Ali MA; McClurkan CL; Soto S; Ahn IE; Nierman P; Maddux E; Lotter J; Superata J; Tian X; Wiestner A; Cohen JI; Koelle DM; Sun C
    Blood Adv; 2022 Mar; 6(6):1732-1740. PubMed ID: 35157769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis.
    Muchtar E; Koehler AB; Johnson MJ; Rabe KG; Ding W; Call TG; Leis JF; Kenderian SS; Hayman SR; Wang Y; Hampel PJ; Holets MA; Darby HC; Slager SL; Kay NE; Miao C; Canniff J; Whitaker JA; Levin MJ; Schmid DS; Kennedy RB; Weinberg A; Parikh SA
    Am J Hematol; 2022 Jan; 97(1):90-98. PubMed ID: 34699616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of COVID-19 in patients with CLL: a multicenter international experience.
    Mato AR; Roeker LE; Lamanna N; Allan JN; Leslie L; Pagel JM; Patel K; Osterborg A; Wojenski D; Kamdar M; Huntington SF; Davids MS; Brown JR; Antic D; Jacobs R; Ahn IE; Pu J; Isaac KM; Barr PM; Ujjani CS; Geyer MB; Berman E; Zelenetz AD; Malakhov N; Furman RR; Koropsak M; Bailey N; Hanson L; Perini GF; Ma S; Ryan CE; Wiestner A; Portell CA; Shadman M; Chong EA; Brander DM; Sundaram S; Seddon AN; Seymour E; Patel M; Martinez-Calle N; Munir T; Walewska R; Broom A; Walter H; El-Sharkawi D; Parry H; Wilson MR; Patten PEM; Hernández-Rivas JÁ; Miras F; Fernández Escalada N; Ghione P; Nabhan C; Lebowitz S; Bhavsar E; López-Jiménez J; Naya D; Garcia-Marco JA; Skånland SS; Cordoba R; Eyre TA
    Blood; 2020 Sep; 136(10):1134-1143. PubMed ID: 32688395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis.
    Dagnew AF; Ilhan O; Lee WS; Woszczyk D; Kwak JY; Bowcock S; Sohn SK; Rodriguez Macías G; Chiou TJ; Quiel D; Aoun M; Navarro Matilla MB; de la Serna J; Milliken S; Murphy J; McNeil SA; Salaun B; Di Paolo E; Campora L; López-Fauqued M; El Idrissi M; Schuind A; Heineman TC; Van den Steen P; Oostvogels L;
    Lancet Infect Dis; 2019 Sep; 19(9):988-1000. PubMed ID: 31399377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors.
    Ryan CE; Cheng MP; Issa NC; Brown JR; Davids MS
    Blood Adv; 2020 Apr; 4(7):1458-1463. PubMed ID: 32282880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged ≥50 years: A randomized trial.
    Strezova A; Lal H; Enweonye I; Campora L; Beukelaers P; Segall N; Heineman TC; Schuind AE; Oostvogels L
    Vaccine; 2019 Sep; 37(39):5877-5885. PubMed ID: 31443993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma.
    Zent CS; Brady MT; Delage C; Strawderman M; Laniewski N; Contant PN; Kanagaiah P; Sangster MY; Barr PM; Chu CC; Topham DJ; Friedberg JW
    Leukemia; 2021 Jun; 35(6):1788-1791. PubMed ID: 33128020
    [No Abstract]   [Full Text] [Related]  

  • 9. The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70.
    Boutry C; Hastie A; Diez-Domingo J; Tinoco JC; Yu CJ; Andrews C; Beytout J; Caso C; Cheng HS; Cheong HJ; Choo EJ; Curiac D; Di Paolo E; Dionne M; Eckermann T; Esen M; Ferguson M; Ghesquiere W; Hwang SJ; Avelino-Silva TJ; Kosina P; Liu CS; Markkula J; Moeckesch B; Murta de Oliveira C; Park DW; Pauksens K; Pirrotta P; Plassmann G; Pretswell C; Rombo L; Salaun B; Sanmartin Berglund J; Schenkenberger I; Schwarz T; Shi M; Ukkonen B; Zahaf T; Zerbini C; Schuind A; Cunningham AL;
    Clin Infect Dis; 2022 Apr; 74(8):1459-1467. PubMed ID: 34283213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune responses to zoster vaccines.
    Levin MJ; Weinberg A
    Hum Vaccin Immunother; 2019; 15(4):772-777. PubMed ID: 30676834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination.
    Hastie A; Catteau G; Enemuo A; Mrkvan T; Salaun B; Volpe S; Smetana J; Rombo L; Schwarz T; Pauksens K; Hervé C; Bastidas A; Schuind A
    J Infect Dis; 2021 Dec; 224(12):2025-2034. PubMed ID: 32502272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention.
    Lecrenier N; Beukelaers P; Colindres R; Curran D; De Kesel C; De Saegher JP; Didierlaurent AM; Ledent EY; Mols JF; Mrkvan T; Normand-Bayle M; Oostvogels L; Da Silva FT; Vassilev V; Vinals C; Brecx A
    Expert Rev Vaccines; 2018 Jul; 17(7):619-634. PubMed ID: 30028651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry/ethnicity: A post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials.
    Willer DO; Oostvogels L; Cunningham AL; Gervais P; Gorfinkel I; Hyung Kim J; Talarico C; Wascotte V; Zahaf T; Colindres R; Schuind A;
    Vaccine; 2019 Oct; 37(43):6262-6267. PubMed ID: 31537443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-licensure safety study of new-onset immune-mediated diseases, herpes zoster, and anaphylaxis in adult recipients of HepB-CpG vaccine versus HepB-alum vaccine.
    Ackerson B; Sy LS; Slezak J; Qian L; Reynolds K; Huang R; Solano Z; Towner W; Qiu S; Simmons SR; Jacobsen SJ; Bruxvoort KJ
    Vaccine; 2023 Jul; 41(30):4392-4401. PubMed ID: 37308363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice.
    Stadtmauer EA; Sullivan KM; El Idrissi M; Salaun B; Alonso Alonso A; Andreadis C; Anttila VJ; Bloor AJ; Broady R; Cellini C; Cuneo A; Dagnew AF; Di Paolo E; Eom H; González-Rodríguez AP; Grigg A; Guenther A; Heineman TC; Jarque I; Kwak JY; Lucchesi A; Oostvogels L; Polo Zarzuela M; Schuind AE; Shea TC; Sinisalo UM; Vural F; Yáñez San Segundo L; Zachée P; Bastidas A
    Hum Vaccin Immunother; 2021 Nov; 17(11):4144-4154. PubMed ID: 34406911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials.
    López-Fauqued M; Co-van der Mee M; Bastidas A; Beukelaers P; Dagnew AF; Fernandez Garcia JJ; Schuind A; Tavares-da-Silva F
    Drug Saf; 2021 Jul; 44(7):811-823. PubMed ID: 34115324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A practitioner's guide to the recombinant zoster vaccine: review of national vaccination recommendations.
    Parikh R; Widenmaier R; Lecrenier N
    Expert Rev Vaccines; 2021 Sep; 20(9):1065-1075. PubMed ID: 34311643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody response to revaccination among adult non-responders to primary Hepatitis B vaccination in China.
    Zhang L; Liu J; Lu J; Yan B; Song L; Li L; Cui F; Zhang G; Wang F; Liang X; Xu A
    Hum Vaccin Immunother; 2015; 11(11):2716-22. PubMed ID: 26252481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects.
    Palma M; Mulder TA; Österborg A
    Front Immunol; 2021; 12():686768. PubMed ID: 34276674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL.
    Mhibik M; Wiestner A; Sun C
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31861854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.